TrialMolecular metabolism2026

Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies.

William Roell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.